Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alt trial (WJOG10818L)
jRCTs051180009Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: One-year progression-free survival rate. Started Nov 2018; status: completed.
02
Drugs
osimertinibafatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051180009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180009.